UNSPSC 51142035: Ziconotide

This classification denotes a nonnarcotic analgesic with the molecular formula C102H172N36O32S7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7I64C51O16, chemically known as omega-conotoxin m viia (reduced), cyclic (1-16),(8-20),(15-25)-tris(disulfide) but generally known as ziconotide, which bears US NIH Compound Identifier 16129690. European Medicines Agency schedules Ziconotide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00150MIG.

UNSPSC 51142035 Ziconotide is a Commodity code nominally designating a specific pharmaceutical active ingredient, but recent state and local solicitations tagged under it span a broader range of pharmaceutical procurement — naloxone (opioid-reversal medication), over-the-counter and generic pharmaceuticals, and direct-to-manufacturer prescription programs. State and local governments are using this code to procure pharmaceutical products, medical supplies, and pharmacy benefit management services through competitive bidding, cooperative purchasing agreements, and exploratory requests for information. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, which includes participating jurisdictions across Minnesota, Oregon, and other states). The scope reflects procurement for community health initiatives, employee and retiree pharmacy benefits, and opioid-response infrastructure.

Recent opportunities show geographic activity centered in Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida; the contract carries a two-year initial term with one-year renewal option and potential FEMA funding. The Texas HHS Commission released RFI HHS0017013 (posted April 3, 2026, response deadline April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program serving self-insured state employee and retiree plans. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP (posted January 20, 2026, due March 26, 2026) to establish multivendor contracts for generic and over-the-counter pharmaceuticals distributed through authorized wholesalers across participating state and local facilities; the contract is weighted 75 percent on price competitiveness and requires cGMP certification and Drug Supply Chain Security Act compliance. No set-aside designations are specified in the recent opportunities.